Abstract
p38 mitogen-activated protein kinase (MAPK) is a pivotal enzyme in the biosynthesis of pro-inflammatory cytokines like IL-1 and TNF. Therefore, the success of anti-cytokine therapy for treatment of inflammatory processes qualified p38-MAPK as a solid target in drug research concerning chronic inflammatory diseases including infectious vascular, neurobiological, and autoimmune disorders. However, the discovery of new kinase inhibitors is limited by the need for a high biological activity combined with restricted activity to the target enzyme or pathway interaction. As a consequence, no p38 MAPK inhibitor has been introduced to the market so far, although several p38 inhibitors have proceeded into clinical trials. The development of novel inhibitor types and optimization of already known structural classes of MAPK inhibitors require appropriate testing systems reaching across these crucial parameters. As a new approach, we describe the sequential arrangement of three testing systems custom-tailored to the requirements of drug discovery programs with focus on p38 inhibition. Integrated analysis of the obtained results enables a concerted step-by-step selection of tested molecules in order to screen a compound library for the most suitable inhibitor. First, evaluation of the inhibitor’s activity on the isolated p38 MAPK enzyme via an ELISA assay gives a first idea about the inhibitory potency of the molecule. Moreover, structure-activity relationships can be elucidated when comparing molecules within inhibitor series. Second, screening in living cells via a p38 substrate-specific MK2-EGFP translocation assay supplies further information about efficacy, but provides also a first notion concerning selectivity and toxicity. Third, efficacy is evaluated more specifically in vivo in LPS-stimulated human whole blood with regard to in vivo parameters, e.g., pharmacokinetic characteristics like plasma protein binding and cellular permeability. These three testing systems complement one another synergistically by providing a high overlap and predictability. Clear advantages of all presented systems are their realizability in an academic environment as well as their applicability for high-throughput screenings on a larger scale.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Coulthard LR et al (2009) p38(MAPK): stress responses from molecular mechanisms to therapeutics. Trends Mol Med 15(8):369–379
Korb A et al (2006) Differential tissue expression and activation of p38 MAPK alpha, beta, gamma, and delta isoforms in rheumatoid arthritis. Arthritis Rheum 54(9):2745–2756
Schett G, Zwerina J, Firestein G (2008) The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis. Ann Rheum Dis 67(7):909–916
Zarubin T, Han JH (2005) Activation and signaling of the p38 MAP kinase pathway. Cell Res 15(1):11–18
Kumar S, Boehm J, Lee JC (2003) p38 map kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2(9):717–726
Goettert M, Graeser R, Laufer SA (2010) Optimization of a nonradioactive immunosorbent assay for p38alpha mitogen-activated protein kinase activity. Anal Biochem 406(2):233–234
Anton R et al (2014) A p38 substrate-specific MK2-EGFP Translocation assay for identification and validation of new p38 inhibitors in living cells: a comprising alternative for acquisition of cellular p38 inhibition data. PLoS One 9(4):e95641
Engel K, Kotlyarov A, Gaestel M (1998) Leptomycin B-sensitive nuclear export of MAPKAP kinase 2 is regulated by phosphorylation. EMBO J 17(12):3363–3371
Williams RG et al (2006) Generation and characterization of a stable MK2-EGFP cell line and subsequent development of a high-content imaging assay on the Cellomics ArrayScan platform to screen for p38 mitogen-activated protein kinase inhibitors. Methods Enzymol 414:364–389
Trask OJ et al (2009) High-throughput automated confocal microscopy imaging screen of a kinase-focused library to identify p38 mitogen-activated protein kinase inhibitors using the GE InCell 3000 analyzer. Methods Mol Biol 565:159–186
Ross S et al (2006) High-content screening analysis of the p38 pathway: profiling of structurally related p38alpha kinase inhibitors using cell-based assays. Assay Drug Dev Technol 4(4):397–409
Thurm CW, Halsey JF (2005) Measurement of cytokine production using whole blood. Curr Protoc Immunol Chapter 7: p. Unit 7 18B
Zhang JH, Chung TDY, Oldenburg KR (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4(2):67–73
Acknowledgement
The authors would like to thank Stefanie Mocka, Carolin Klein, Anke Friedrichs, Dr. Sabine Luik, Dr. Sabine Linsenmeier, Dr. Cornelia Greim, and K. Bauer for their valuable contributions to the establishment and optimization of the herein presented whole blood assay.
UR gratefully acknowledges the Ministry of Science, Research and Arts of Baden-Württemberg (V.1.4.-H3-1403-74) for financial support.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Bauer, S.M., Kubiak, J.M., Rothbauer, U., Laufer, S. (2016). From Enzyme to Whole Blood: Sequential Screening Procedure for Identification and Evaluation of p38 MAPK Inhibitors. In: Zegzouti, H., Goueli, S. (eds) Kinase Screening and Profiling. Methods in Molecular Biology, vol 1360. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3073-9_10
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3073-9_10
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3072-2
Online ISBN: 978-1-4939-3073-9
eBook Packages: Springer Protocols